EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

OP0177 Randomized Comparison of Triple Dmard Therapy with Methotrexate Mono-Therapy

(2014) P. H. P. De Jong et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0022 Abatacept sc versus adalimumab on background methotrexate in RA: One year results from the ample study

(2014) M. Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0023 Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: Results of a phase 2, randomized, double-blind, placebo-controlled, international study

(2014) T.W. Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0297 Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen.

(2014) A. Batticciotto et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0296 Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis

(2014) A. Nampei et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra)

(2014) J. Morel et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0067 Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination with Adalimumab: Results from the Concerto Trial

(2014) G. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0066 Targeting the Lowest Efficacious Dose for Rheumatoid Arthritis Patients in Remission: Clinical and Structural Impact of a Step-Down Strategy Trial Based on Progressive Spacing of TNF-Blocker Injections (Strass Trial)

(2014) B. Fautrel et al.   ANNALS OF THE RHEUMATIC DISEASES

LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial:

(2014) C. Gabay et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Cécile Gaujoux-Viala et al.   ANNALS OF THE RHEUMATIC DISEASES

Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis

(2013) Marije F. Bakker   ANNALS OF INTERNAL MEDICINE

Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Sonographic Joint Assessment in Rheumatoid Arthritis: Associations With Clinical Joint Assessment During a State of Remission

(2013) Miriam Gärtner et al.   ARTHRITIS AND RHEUMATISM

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic—data from the ATTRA registry

(2013) Pavel Horák et al.   CLINICAL RHEUMATOLOGY

Association Between the Initiation of Anti–Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster

(2013) Kevin L. Winthrop et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market

(2013) Ken Garber   NATURE BIOTECHNOLOGY

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

(2013) James R. O'Dell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

(2013) Y Hishitani et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

The new 2012 German recommendations for treating rheumatoid arthritis

(2013) J. Wollenhaupt et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Safety of Surgery After Rituximab Therapy in 133 Patients With Rheumatoid Arthritis: Data From the AutoImmunity and Rituximab Registry

(2013) S. Godot et al.   ARTHRITIS CARE & RESEARCH

In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis

(2012) Garifallia Sakellariou et al.   ANNALS OF THE RHEUMATIC DISEASES

Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index

(2012) Daniel Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and

(2012) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

(2012) Marjatta Leirisalo-Repo et al.   ANNALS OF THE RHEUMATIC DISEASES

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

(2012) Jacqueline Detert et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

(2012) P H de Jong et al.   ANNALS OF THE RHEUMATIC DISEASES

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

(2012) P Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical evaluation of the efficacy of the P2X7purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine

(2012) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

(2012) Monika Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

(2012) Charlotte L. Krieckaert et al.   ARTHRITIS AND RHEUMATISM

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

(2012) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

(2012) Larry W. Moreland et al.   ARTHRITIS AND RHEUMATISM

Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?

(2012) Bassel El Zorkany et al.   CLINICAL RHEUMATOLOGY

Factors Associated With the Initiation of Disease-Modifying Antirheumatic Drugs in Newly Diagnosed Rheumatoid Arthritis: A Retrospective Claims Database Study

(2012) Machaon M.K. Bonafede et al.   CLINICAL THERAPEUTICS

Hydroxychloroquine Use and Decreased Risk of Diabetes in Rheumatoid Arthritis Patients

(2012) Androniki Bili et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

(2012) Ronald F van Vollenhoven et al.   LANCET

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Christopher J L Murray et al.   LANCET

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Theo Vos et al.   LANCET

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies

(2012) D. van der Woude et al.   RHEUMATOLOGY

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study

(2011) N. B. Klarenbeek et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis: Table 1

(2011) Yvonne van Eijk-Hustings et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

(2011) D. T. Felson et al.   ANNALS OF THE RHEUMATIC DISEASES

Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis

(2011) N. B. Klarenbeek et al.   ANNALS OF THE RHEUMATIC DISEASES

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints

(2011) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action

(2011) Steven J Katz et al.   CURRENT OPINION IN RHEUMATOLOGY

Etanercept Compared to Intraarticular Corticosteroid Injection in Rheumatoid Arthritis: Double-blind, Randomized Pilot Study

(2011) C. H. ROUX et al.   JOURNAL OF RHEUMATOLOGY

Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs

(2011) VIVIAN P. BYKERK et al.   JOURNAL OF RHEUMATOLOGY

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) R. Knevel et al.   ANNALS OF THE RHEUMATIC DISEASES

A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study

(2010) E. van der Kooi et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) S. L. Gorter et al.   ANNALS OF THE RHEUMATIC DISEASES

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) M. Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) C. Gaujoux-Viala et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study

(2010) N. B. Klarenbeek et al.   ANNALS OF THE RHEUMATIC DISEASES

A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study

(2010) K. Visser et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

(2010) J. L. Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

(2010) Y. Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: Meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons

(2010) Niels Graudal et al.   ARTHRITIS AND RHEUMATISM

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology

(2010) Chi Chiu Mok et al.   CLINICAL RHEUMATOLOGY

Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice

(2010) K. Montag et al.   INTERNAL MEDICINE JOURNAL

Use of glucocorticoids in rheumatoid arthritis – Pratical modalities of glucocorticoid therapy: Recommendations for clinical practice based on data from the literature and expert opinion

(2010) Emmanuelle Dernis et al.   JOINT BONE SPINE

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

(2010) S. L. Westlake et al.   RHEUMATOLOGY

Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard

(2010) A. Balsa et al.   RHEUMATOLOGY

Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN)

(2010) P. Kiely et al.   RHEUMATOLOGY

Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis

(2010) H. Radner et al.   RHEUMATOLOGY

Quality care in seniors with new-onset rheumatoid arthritis: A Canadian perspective

(2010) Jessica Widdifield et al.   ARTHRITIS CARE & RESEARCH

Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients

(2010) Stephanie J. Morris et al.   ARTHRITIS CARE & RESEARCH

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

(2009) R. O'Mahony et al.   ANNALS OF THE RHEUMATIC DISEASES

Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008

(2009) M. Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness of tumour necrosis factor   inhibitors in combination with either methotrexate or leflunomide

(2009) A Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

(2009) M J L Peters et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

(2009) R Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment

(2009) D. Aletaha et al.   ARTHRITIS AND RHEUMATISM

Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis

(2009) Olivier Brocq et al.   JOINT BONE SPINE

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

(2009) RF van Vollenhoven et al.   LANCET

Management of RA medications in pregnant patients

(2009) Monika Østensen et al.   Nature Reviews Rheumatology

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial

(2009) M. Soubrier et al.   RHEUMATOLOGY

The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

(2009) S. L. Westlake et al.   RHEUMATOLOGY

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis

(2009) Nathan Vastesaeger et al.   RHEUMATOLOGY

Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis

(2008) W Katchamart et al.   ANNALS OF THE RHEUMATIC DISEASES

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

(2008) J S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

(2008) K Visser et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

(2008) D Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

The importance of reporting disease activity states in rheumatoid arthritis clinical trials

(2008) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

(2007) A Gonzalez et al.   ANNALS OF THE RHEUMATIC DISEASES